OnKure Therapeutics (OKUR) Stock
What OnKure Therapeutics's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -2.40x
- Debt / equity
- 0.00x
What OnKure Therapeutics's price implies
OnKure Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from OnKure Therapeutics's 10-K filings.
OnKure Therapeutics revenue and free cash flow
FY2020–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | — |
| Net income | -$40M | -$52M | -$35M | -$53M | -$60M |
| Free cash flow | -$38M | -$48M | -$35M | -$51M | -$52M |
| EPS (diluted) | -$21.90 | -$21.20 | -$124.41 | -$15.28 | -$4.40 |
| Operating margin | — | — | — | — | — |
Superinvestors who own OKUR
From each investor's latest 13F filing (what a 13F shows). All 4 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Ensign Peak Ensign Peak Advisors | New position | $2M | 0.00% | Q2 2026 |
| Jim Simons Renaissance Technologies | Trimmed | $2M | 0.00% | Q2 2026 |
| Paul Marshall Marshall Wace | Added | $729,057 | 0.00% | Q2 2026 |
| Two Sigma Two Sigma Investments | Added | $496,447 | 0.0% | Q2 2026 |
OnKure Therapeutics insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of OKUR in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from OKUR's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How OnKure Therapeutics compares
OnKure Therapeutics's ROE is higher than 32% of Healthcare companies and 11% of the 3,455 companies with an ROE figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| ROE | 32% | 11% |
Questions about OnKure Therapeutics
Are OnKure Therapeutics insiders buying the stock?
No open-market insider purchases of OKUR in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own OnKure Therapeutics?
4 of the superinvestors Investingly tracks hold OKUR in their latest 13F, including Ensign Peak, Jim Simons, Paul Marshall.
Companies like OnKure Therapeutics
ProQR Therapeutics N.V. (PRQR)$136MPyxis Oncology, Inc. (PYXS)$136MJyong Biotech Ltd. (MENS)$136MArmata Pharmaceuticals Inc (ARMP)$139MSpruce Biosciences, Inc. (SPRB)$134MAbeona Therapeutics Inc (ABEO)$141MZura Bio Ltd (ZURA)$133MKorsana Biosciences, Inc. (KRSA)$132MCanton Strategic Holdings, Inc. (CNTN)$144M All Healthcare stocks→Prices and ratios as of Nov 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.